Literature DB >> 19207760

The relationship of bipolar left ventricular pacing stimulus intensity to cardiac depolarization and repolarization in humans with cardiac resynchronization devices.

Cathrin Theis1, Venkata V Bavikati, Jonathan J Langberg, Michael S Lloyd.   

Abstract

BACKGROUND: Myocardial depolarization can be altered by varying pacing stimulus output. This may have implications on response rates for cardiac resynchronization therapy (CRT). The purpose of our study was to determine the relationship of left ventricular (LV) pacing stimulus intensity to measures of depolarization and repolarization in humans with CRT devices.
METHODS: In 37 patients with a CRT device and bipolar LV leads, bipolar LV-only pacing from maximum output to threshold was performed. The presence of changes in depolarization was defined by predetermined changes in ECG morphology that accompanied a change in bipolar stimulus amplitude. ECG parameters and the EGMs were analyzed at various LV pacing stimulus intensities.
RESULTS: Changes in ECG morphology were apparent in 70% of patients. These occurred at a mean LV stimulus amplitude of greater than 2.7 +/- 0.8 V at 1 ms. Of the patients with changes in surface ECG, the transventricular conduction time decreased from 155 +/- 41 ms at low output to 141 +/- 39 ms at high output (P < 0.01). Despite a significant reduction in QRS duration with high output, mean QTc and JTc interval increased with increasing LV stimulus strength (539 +/- 45 vs 559 +/- 46 ms (P < 0.01) and 353 +/- 31 ms vs 377 +/- 32 (P < 0.01)).
CONCLUSION: Increased LV stimulus intensity, independent of RV anodal capture, is associated with faster transventricular conduction time, changes in myocardial depolarization, and longer QT intervals. These findings have important implications on the relationship of programmed LV pacing output to pacing-induced proarrhythmia and clinical CRT response rates.

Entities:  

Mesh:

Year:  2009        PMID: 19207760     DOI: 10.1111/j.1540-8167.2008.01378.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

1.  High-amplitude left ventricular pacing in cardiac resynchronization therapy: an alternative way to increase response rate in non-responders.

Authors:  Halit Zengin; Filiz Akın; Sabri Demircan; Korhan Soylu; Alirıza Erbay; Serkan Yuksel; Murat Meric; Okan Gulel; Mahmut Sahin; Ozcan Yılmaz
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

2.  Rationale and design of a randomized trial to assess the safety and efficacy of MultiPoint Pacing (MPP) in cardiac resynchronization therapy: The MPP Trial.

Authors:  Gery Tomassoni; James Baker; Raffaele Corbisiero; Charles Love; David Martin; Robert Sheppard; Seth J Worley; Kwangdeok Lee; Imran Niazi
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05-18       Impact factor: 1.468

3.  Effect of cardiac resynchronization therapy on ventricular repolarization: a meta-analysis.

Authors:  Xu Duan; Wei Gao
Journal:  Anatol J Cardiol       Date:  2014-02-26       Impact factor: 1.596

4.  Stimulus intensity in left ventricular leads and response to cardiac resynchronization therapy.

Authors:  Venkata V Bavikati; Jonathan J Langberg; B Robinson Williams; Danesh Kella; Michael S Lloyd
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

5.  Clinical impact of increasing left ventricular pacing output in cardiac resynchronization therapy - the new optimization strategy.

Authors:  Kohei Ishibashi; Takashi Noda; Ikutaro Nakajima; Hideo Okamura; Hideaki Kanzaki; Kengo Kusano
Journal:  Clin Case Rep       Date:  2016-05-25

6.  Association left ventricular lead and ventricular arrhythmias after upgrade to cardiac resynchronization therapy in patients with implantable cardioverter defibrillators.

Authors:  Mitsuharu Kawamura; Shuhei Arai; Kosuke Yoshikawa; Toshihiko Gokan; Ko Ogawa; Akinori Ochi; Yoshimi Onishi; Yumi Munetsugu; Hiroyuki Ito; Tatsuya Onuki; Youichi Kobayashi; Toshiro Shinke
Journal:  Clin Cardiol       Date:  2019-05-13       Impact factor: 2.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.